An update on the novel and approved drugs for Alzheimer disease

Abdallah, 2010, Synthesis and spectroscopic characterization of new tetradentate Schiff base and its coordination compounds of NOON donor atoms and their antibacterial and antifungal activity, Arabian J. Chem., 3, 103, 10.1016/j.arabjc.2010.02.006 Ahmed, 2019, Current agents in development for treating behavioral and psychological symptoms associated with dementia, Drugs Aging, 36, 589, 10.1007/s40266-019-00668-7 Anand, 2017, The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review, Eur. J. Pharmacol., 815, 364, 10.1016/j.ejphar.2017.09.043 Ansari, 2013, Natural products as promising drug candidates for the treatment of Alzheimer’s disease: molecular mechanism aspect, Curr. Neuropharmacol., 11, 414, 10.2174/1570159X11311040005 Arndt, J.W., Qian, F., Smith, B.A., Quan, C., Kilambi, K.P., Bush, M.W., Walz, T., Pepinsky, R.B., Bussiere, T., Hamann, S., Cameron, T.O., Weinreb., 2018. PH: Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci Rep. 8(1):6412. doi: 10.1038/s41598-018-24501-0 Atri, 2019, Current and future treatments in Alzheimer’s disease, Semin. Neurol., 39, 227, 10.1055/s-0039-1678581 Bandegi, A.R., Rashidy-Pour, A., Vafaei, A.A., Ghadrdoost, B., 2014. Protective Effects of Crocus Sativus L. Extract and Crocin against Chronic-Stress Induced Oxidative Damage of Brain, Liver and Kidneys in Rats. Adv Pharm Bull. 4:493-499. https://dx.doi.org/10.5681%2Fapb.2014.073. Bendova, 2010, Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury, Chem. Res. Toxicol., 23, 1105, 10.1021/tx100125t Biasibetti, 2013, Green tea (−) epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia, Behav. Brain Res., 236, 186, 10.1016/j.bbr.2012.08.039 Bihaqui, 2012, Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and Amyloid precursor protein (AβPP) expression in rat brain, Indian J. Pharmacol., 44, 593, 10.4103/0253-7613.100383 Bishop, 2004, Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease, Drugs Aging, 21, 621, 10.2165/00002512-200421100-00001 Bondi, 2017, Alzheimer’s disease: past, present, and future, J. Int. Neuropsychol. Soc., 23, 818, 10.1017/S135561771700100X Budimir, 2011, Metal ions, Alzheimer's disease, and chelation therapy, Acta Pharm., 61, 1, 10.2478/v10007-011-0006-6 Calvó-Perxas, 2017, Trends in the prescription and long-term utilization of antidementia drugs among patients with Alzheimer's disease in Spain: a cohort study using the registry of dementias of girona. registry of dementias of girona study group (ReDeGi Study Group), Drugs Aging, 34, 303, 10.1007/s40266-017-0446-x Chakravarthi, 2013, Beneficial effect of aqueous root extract of Glycyrrhiza glabra on learning and memory using different behavioral models: an experimental study, J. Nat. Sci. Biol. Med., 420–425 Chang, 2015, (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer’s disease model mice by upregulating neprilysin expression, Exp. Cell Res., 334, 136, 10.1016/j.yexcr.2015.04.004 Cho, 2014, ID1201, the ethanolic extract of the fruit of Melia toosendan ameliorates impairments in spatial learning and reduces levels of amyloid beta in 5XFAD mice, Neurosci. Lett., 583, 170, 10.1016/j.neulet.2014.09.036 Clarke, 1992, Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions, Inorg. Chim. Acta, 191, 57, 10.1016/S0020-1693(00)80327-8 Coleman, 2017, The discovery of suvorexant, the first orexin receptor drug for insomnia, Annu. Rev. Pharmacol. Toxicol., 57, 509, 10.1146/annurev-pharmtox-010716-104837 Coric, 2015, Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial, JAMA Neurol., 72, 1324, 10.1001/jamaneurol.2015.0607 Cummings, J., Lee, G., Ritter, A., Sabbagh, M., Zhong, K., 2019.Alzheimer’s disease drug development pipeline: 2019Alzheimers Dement. 5:272-293. https://doi.org/10.1016/j.trci.2019.05.008. Defeudis, 2002, Bilobalide and neuroprotection, Pharmacol. Res., 46, 565, 10.1016/S1043-6618(02)00233-5 Deraeve, C., Pitíe, M., Mazarguil, H., Meunier, B., 2007. Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents, New J. Chem., 31, 193–195. https://doi.org/10.1039/B616085A Doody, 2013, A phase 3 trial of semagacestat for treatment of Alzheimer’s disease, N. Engl. J. Med., 369, 341, 10.1056/NEJMoa1210951 Dunstan, 2011, The role of brain macrophages on the clearance of amyloid plaques following the treatment of Tg2576 with BIIB037, Alzheimers Dement. l, 7, S700 Egan, 2019, Randomized trial of verubecestat for prodromal Alzheimer’s disease, N. Engl. J. Med., 380, 1408, 10.1056/NEJMoa1812840 Ferrada, V., Arancibia, B., Loeb, E., Norambuena, C., OleaAzar., Huidobro-Toro, J.P., 2007. Neurotoxicology. 28, 445–449. https://doi.org/10.1016/j.neuro.2007.02.004. Ferrero, 2016, First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease, Alzheimers Dement (N Y), 2, 169, 10.1016/j.trci.2016.06.002 Francis, 2005, The interplay of neurotransmitters in Alzheimer's disease, CNS Spectrums, 10, 6, 10.1017/S1092852900014164 Galimberti, 2017, Pioglitazone for the treatment of Alzheimer’s disease, Expert. Opin. Investig. Drugs, 26, 97, 10.1080/13543784.2017.1265504 Hardy, 2002, The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 He, 2014, Neuroprotective effects of ginsenoside Rg1 against oxygen-glucose deprivation in cultured hippocampal neurons, J. Chin. Med. Assoc., 77, 142, 10.1016/j.jcma.2014.01.001 Henley, 2019, Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease, N. Engl. J. Med., 380, 1483, 10.1056/NEJMc1813435 Herring, 2019, Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications, J. Sleep Res., 28, e12782, 10.1111/jsr.12782 Hoi, 2010, Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells, Phytother. Res., 24, 1538, 10.1002/ptr.3178 Huang, 2020, Clinical trials of new drugs for Alzheimer disease, J. Biomed. Sci., 27, 18, 10.1186/s12929-019-0609-7 Huang, 2017, Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β-amyloid in APP/ tau/PS1 mouse model of Alzheimer’s disease, Exp. Gerontol., 91, 25, 10.1016/j.exger.2017.02.004 Hull, 2017, Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer’s disease, Curr. Alzheimer Res., 14, 696, 10.2174/1567205014666170117101537 Jeong, 2014, Neuroprotective biflavonoids of Chamaecyparis obtusa leaves against glutamate-induced oxidative stress in HT22 hippocampal cells, Food Chem. Toxicol., 64, 397, 10.1016/j.fct.2013.12.003 Kishita, 2020, Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with Dementia: an overview of systematic reviews, Geriatr. Psychiatry Neurol., 33, 28, 10.1177/0891988719856690 Krishnankutty., John, V., 2003. Synthesis, Characterization, and Antitumour Studies of Metal Chelates of Some Synthetic Curcuminoids Synth. React. Inorg. Met. Org. Chem. 33, 343–358. https://doi.org/10.1081/SIM-120017791 Lautenschläger, 2015, Intestinal formation of trans-crocetin from saffron extract (Crocus sativus L.) and in vitro permeation through intestinal and blood brain barrier, Phytomedicine, 22, 36, 10.1016/j.phymed.2014.10.009 Lawlor, 2018, Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial, PLoS Med., 15, e1002660, 10.1371/journal.pmed.1002660 Lee, 2009, Green tea (-)-epigallocatechin-3-gallate inhibits β-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-κB pathways in mice, J. Nutr., 139, 1987, 10.3945/jn.109.109785 Lim, 2001, The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse, J. Neurosci., 21, 8370, 10.1523/JNEUROSCI.21-21-08370.2001 Liu, 2014, Catalpol provides protective effects against cerebral ischaemia/reperfusion injury in gerbils, J. Pharm. Pharmacol., 66, 1265, 10.1111/jphp.12261 Liu, 2014, Ginsenoside Rb1 protects hippocampal neurons from high glucose-induced neurotoxicity by inhibiting GSK3β-mediated CHOP induction, Mol. Med. Rep., 9, 1434, 10.3892/mmr.2014.1958 Lopez, 2019, The Alzheimer’s Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease, Alzheimers Dement., 5, 216, 10.1016/j.trci.2019.02.005 Molinuevo, 2005, Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias, Am. J. Alzheimers Dis. Other Demen., 20, 77, 10.1177/153331750502000206 Muntimadugu, 2016, Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer’s disease, Eur. J. Pharm. Sci., 92, 224, 10.1016/j.ejps.2016.05.012 Murakami, 2019, Three structural features of functional food components and herbal medicine with amyloid β42 anti-aggregation properties, Molecules, 24, 2125, 10.3390/molecules24112125 Olajide, 2017, Ascorbic acid ameliorates behavioural deficits and neuropathological alterations in rat model of Alzheimer’s disease, Environ. Toxicol. Pharmacol., 50, 200, 10.1016/j.etap.2017.02.010 Ostrowitzki, 2017, SCarlet RoAD Investigators. a phase III randomized trial of gantenerumab in prodromal Alzheimer's disease, Alzheimers Res. Ther., 9, 95, 10.1186/s13195-017-0318-y Panza, 2018, The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset, Expert. Opin. Biol. Ther., 18, 25, 10.1080/14712598.2018.1389885 Pfaender, 2014, Characterization of biometal profiles in neurological disorders, Metallomics, 6, 960, 10.1039/C4MT00008K Prince, 2013, The global prevalence of dementia: a systematic review and metaanalysis, Alzheimers Dement., 9, 63, 10.1016/j.jalz.2012.11.007 Rafii, 2011, A phase II trial of huperzine a in mild to moderate Alzheimer disease, Neurology, 76, 1389, 10.1212/WNL.0b013e318216eb7b Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., Mobius, HJ., 2003. Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348, 1333–1341. http:// dx.doi.org/10.1056/NEJMoa013128. Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane,S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.X., Tammer A., 2003. Metal-Protein Attenuation with Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease. Arch. Neurol. 60, 1685–1691. 51 A. doi:10.1001/archneur.60.12.1685. Rountree, 2013, Effectiveness of antidementia drugs in delaying Alzheimer's disease progression, Alzheimers Dement., 9, 338, 10.1016/j.jalz.2012.01.002 Salloway, 2011, ELND005-AD201 Investigators. a phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease, Neurology, 77, 1253, 10.1212/WNL.0b013e3182309fa5 Salloway, 2014, Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease, N. Engl. J. Med., 370, 322, 10.1056/NEJMoa1304839 Santos, 2008, Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications: mono and combined ligand approaches, Coord. Chem. Rev., 252, 1213, 10.1016/j.ccr.2008.01.033 Singh, 2013, Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection, Eur. J. Med. Chem., 70, 165, 10.1016/j.ejmech.2013.09.050 Stark, 2017, Peptidomimetics that inhibit and partially reverse the aggregation of Aβ1-42, Biochemistry, 56, 4840, 10.1021/acs.biochem.7b00223 Swerdlow, 2014, The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives, Biochim. Biophys. Acta - Mol. Basis Dis., 1842, 1219, 10.1016/j.bbadis.2013.09.010 Tabet, 2006, Acetylcholinesterase inhibitors for Alzheimer’s disease: anti-inflammatories in acetylcholine clothing!, Age Ageing, 35, 336, 10.1093/ageing/afl027 Tchantchou, 2009, Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons, J. Alzheimers Dis., 18, 787, 10.3233/JAD-2009-1189 Telpoukhovskaia, M.A., Patrick, B.O.C., RodŕıguezRodŕıguez, Orvig, C., 2013. Exploring the multifunctionality of thioflavin- and deferiprone-based molecules as acetylcholinesterase inhibitors for potential application in Alzheimer's disease. Mol. BioSyst., 9, 792–805. https://doi.org/10.1039/C3MB25600F Veldman, 2016, Amyloid binding properties of curcumin analogues in Alzheimer’s disease postmortem brain tissue, Neurosci. Lett., 630, 183, 10.1016/j.neulet.2016.07.045 Vellas, 2011, EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study, Curr. Alzheimer Res., 8, 203, 10.2174/156720511795256053 Wagner, 2012, Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Neurology, 78, 379, 10.1212/WNL.0b013e318245f447 Wang, 2019, Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression, Cell Res., 29, 787, 10.1038/s41422-019-0216-x Wisniewski, 2015, Immunotherapeutic approaches for Alzheimer’s disease, Neuron, 85, 1162, 10.1016/j.neuron.2014.12.064 Yang, 2019, Target engagement in an Alzheimer trial: crenezumab lowers amyloid β oligomers in cerebrospinal fluid, Ann. Neurol., 86, 215, 10.1002/ana.25513 Yang, 2005, Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo, J. Biol. Chem., 280, 5892, 10.1074/jbc.M404751200 Yiannopoulou, K.G., Papageorgiou, S.G., 2020. Current and Future Treatments in Alzheimer Disease: An Update.J Cent Nerv Syst Dis.12:1179573520907397. Published 2020 Feb 29. doi:10.1177/1179573520907397. Yiannopoulou, 2013, Current and future treatments for Alzheimer's disease, Ther. Adv. Neurol. Disord., 6, 19, 10.1177/1756285612461679 Zeng, 2004, Genistein ameliorates beta-amyloid peptide (25–35)-induced hippocampal neuronal apoptosis, Free Radic. Biol. Med., 36, 180, 10.1016/j.freeradbiomed.2003.10.018 Zhao, 2014, Genistein inhibited amyloid-β induced inflammatory damage in C6 glial cells, Arch. Med. Res., 45, 152, 10.1016/j.arcmed.2013.12.008 Zhou, 2014, Relationship between [corrected] spatial memory in diabetic rats and protein kinase Cγ, caveolin-1 in the hippocampus and neuroprotective effect of catalpol, Chin. Med. J. (Engl)., 127, 916 Zhu, 2006, Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer’s disease, BMC Neurosci., 7, 78, 10.1186/1471-2202-7-78